Morbidity and mortality after stroke - Eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES)

被引：5
作者：
Boulanger, JM [1 ]
Hill, MD [1 ]
机构：
[1] Univ Calgary, Calgary, AB T2N 1N4, Canada
来源：
STROKE | 2006年 / 37卷 / 02期
关键词：
D O I：
10.1161/01.STR.0000199659.31103.d2
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：335 / 336
页数：2
相关论文
共 5 条
[1]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[2]   Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial [J].
Julius, S ;
Kjeldsen, SE ;
Weber, M ;
Brunner, HR ;
Ekman, S ;
Hansson, L ;
Hua, TS ;
Laragh, J ;
McInnes, GT ;
Mitchell, L ;
Plat, F ;
Schork, A ;
Smith, B ;
Zanchetti, A .
LANCET, 2004, 363 (9426) :2022-2031
[3]  
PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556, DOI 10.1016/S0140-6736(01)06178-5
[4]   Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention -: Principal results of a prospective randomized controlled study (MOSES) [J].
Schrader, J ;
Lüders, S ;
Kulschewski, A ;
Hammersen, F ;
Plate, K ;
Berger, J ;
Zidek, W ;
Dominiak, P ;
Diener, HC .
STROKE, 2005, 36 (06) :1218-1224
[5]   The ACCESS study -: Evaluation of acute candesartan cilexetil therapy in stroke survivors [J].
Schrader, J ;
Lüders, S ;
Kulschewski, A ;
Berger, J ;
Zidek, W ;
Treib, J ;
Einhäupl, K ;
Diener, HC ;
Dominiak, P .
STROKE, 2003, 34 (07) :1699-1703
1